BAJAJ BROKING

Notification
No new Notification messages
Inventurus Knowledge Solutions IPO is Open!
Apply for the Inventurus Knowledge Solutions IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
medicamen biotech limited stock

MEDICAMEN BIOTECH LIMITED Share Price

564.15 -7.39 (-1.29%)
Dec 13 2024 03:29 PM Pharmaceuticals NSE: MEDICAMEQ

MEDICAMEN BIOTECH LIMITED Share Price Update

As of the latest trading session, MEDICAMEN BIOTECH LIMITED share price is currently at 564.15, which is down by -7.39 from its previous closing. Today, the stock has fluctuated between 561.00 and 594.00. Over the past year, MEDICAMEN BIOTECH LIMITED has achieved a return of -2.85 %. In the last month alone, the return has been 25.21 %. Read More...

MEDICAMEN BIOTECH LIMITED Performance

Day Range

Low561.00 High594.00
565.90

52 Week Range

Low 355.45 High 630.00
565.90

MEDICAMEN BIOTECH LIMITED Share Price

6278

531146

MEDICAMEQ

img img img img
No Data Available

Open Price

567.95

Prev. Close

571.55

Volume (Shares)

38196.00

Total traded value

216.15

Upper Circuit

685.85

Lower Circuit

457.25

Note: The current prices & values are delayed, Login to your account for live updates.

MEDICAMEN BIOTECH LIMITED Fundamentals


(Standalone)

Market Cap (Cr) 717.29
PE Ratio (TTM) 69.08
Book Value / Share 173.40
Beta 1.35
ROE 6.60%
EPS (TTM) 8.18
Dividend Yield 0.18%
Net Profit Qtr (Cr) 2.27

MEDICAMEN BIOTECH LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 42.84
Operating Expense 39.87
Net Profit 2.27
Net Profit Margin (%) 5.29
Earnings Per Share (EPS) 1.78
EBITDA 6.83
Effective Tax Rate (%) 30.46
Particulars JUN 2024 (Values in Cr)
Revenue 41.48
Operating Expense 39.04
Net Profit 2.26
Net Profit Margin (%) 5.44
Earnings Per Share (EPS) 1.78
EBITDA 5.44
Effective Tax Rate (%) 25.16
Particulars MAR 2024 (Values in Cr)
Revenue 45.01
Operating Expense 41.83
Net Profit 3.10
Net Profit Margin (%) 6.88
Earnings Per Share (EPS) 2.45
EBITDA 7.36
Effective Tax Rate (%) 16.62
Particulars DEC 2023 (Values in Cr)
Revenue 44.20
Operating Expense 41.03
Net Profit 2.77
Net Profit Margin (%) 6.26
Earnings Per Share (EPS) 2.19
EBITDA 6.42
Effective Tax Rate (%) 30.92
Particulars SEP 2023 (Values in Cr)
Revenue 42.67
Operating Expense 39.22
Net Profit 3.01
Net Profit Margin (%) 7.05
Earnings Per Share (EPS) 2.38
EBITDA 6.71
Effective Tax Rate (%) 24.75
Particulars MAR 2024 (Values in Cr)
Revenue 172.39
Operating Expense 157.79
Net Profit 13.30
Net Profit Margin (%) 7.71
Earnings Per Share (EPS) 10.50
EBITDA 28.28
Effective Tax Rate (%) 21.25
Particulars MAR 2023 (Values in Cr)
Revenue 137.88
Operating Expense 123.01
Net Profit 15.00
Net Profit Margin (%) 10.87
Earnings Per Share (EPS) 12.04
EBITDA 26.60
Effective Tax Rate (%) 13.44
Particulars MAR 2022 (Values in Cr)
Revenue 115.45
Operating Expense 99.06
Net Profit 14.91
Net Profit Margin (%) 12.91
Earnings Per Share (EPS) 12.20
EBITDA 25.27
Effective Tax Rate (%) 17.67
Particulars MAR 2021 (Values in Cr)
Revenue 110.15
Operating Expense 94.15
Net Profit 12.49
Net Profit Margin (%) 11.33
Earnings Per Share (EPS) 10.22
EBITDA 20.33
Effective Tax Rate (%) 25.43
Particulars MAR 2020 (Values in Cr)
Revenue 117.34
Operating Expense 102.64
Net Profit 12.26
Net Profit Margin (%) 10.44
Earnings Per Share (EPS) 10.09
EBITDA 19.67
Effective Tax Rate (%) 26.20
Particulars MAR 2024 (Values in Cr)
Book Value / Share 162.79
ROE % 4.74
ROCE % 8.14
Total Debt to Total Equity 0.14
EBITDA Margin 14.41
Particulars MAR 2023 (Values in Cr)
Book Value / Share 150.82
ROE % 8.67
ROCE % 10.36
Total Debt to Total Equity 0.15
EBITDA Margin 19.02
Particulars MAR 2022 (Values in Cr)
Book Value / Share 119.89
ROE % 10.67
ROCE % 12.27
Total Debt to Total Equity 0.16
EBITDA Margin 22.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 108.78
ROE % 9.55
ROCE % 12.49
Total Debt to Total Equity 0.12
EBITDA Margin 18.12
Particulars MAR 2020 (Values in Cr)
Book Value / Share 99.22
ROE % 12.79
ROCE % 16.22
Total Debt to Total Equity 0.11
EBITDA Margin 17.06
Particulars MAR 2024 (Values in Cr)
Book Value / Share 164.54
ROE % 6.60
ROCE % 9.76
Total Debt to Total Equity 0.14
EBITDA Margin 17.14
Particulars MAR 2023 (Values in Cr)
Book Value / Share 152.30
ROE % 8.78
ROCE % 10.45
Total Debt to Total Equity 0.15
EBITDA Margin 19.64
Particulars MAR 2022 (Values in Cr)
Book Value / Share 121.18
ROE % 10.56
ROCE % 12.17
Total Debt to Total Equity 0.16
EBITDA Margin 22.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 109.98
ROE % 9.73
ROCE % 12.62
Total Debt to Total Equity 0.12
EBITDA Margin 18.87
Particulars MAR 2020 (Values in Cr)
Book Value / Share 100.25
ROE % 11.73
ROCE % 14.96
Total Debt to Total Equity 0.11
EBITDA Margin 17.07
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 14.78
Total Assets 294.55
Total Liabilities 294.55
Total Equity 206.98
Share Outstanding 12714600
Price to Book Ratio 2.33
Return on Assets (%) 3.71
Return on Capital (%) 4.6
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 20.77
Total Assets 278.51
Total Liabilities 278.51
Total Equity 193.41
Share Outstanding 12651100
Price to Book Ratio 4.30
Return on Assets (%) 5.32
Return on Capital (%) 6.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.82
Total Assets 225.69
Total Liabilities 225.69
Total Equity 146.46
Share Outstanding 12216600
Price to Book Ratio 5.31
Return on Assets (%) 6.60
Return on Capital (%) 8.72
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.89
Total Assets 193.72
Total Liabilities 193.72
Total Equity 132.88
Share Outstanding 12216600
Price to Book Ratio 4.86
Return on Assets (%) 6.26
Return on Capital (%) 8.07
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.09
Total Assets 181.28
Total Liabilities 181.28
Total Equity 121.21
Share Outstanding 12216600
Price to Book Ratio 1.80
Return on Assets (%) 7.33
Return on Capital (%) 10.13
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 14.62
Total Assets 294.21
Total Liabilities 294.21
Total Equity 209.20
Share Outstanding 12714600
Price to Book Ratio 2.33
Return on Assets (%) 4.51
Return on Capital (%) 5.57
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 20.44
Total Assets 276.78
Total Liabilities 276.78
Total Equity 193.79
Share Outstanding 12651100
Price to Book Ratio 4.30
Return on Assets (%) 5.42
Return on Capital (%) 6.88
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.81
Total Assets 225.69
Total Liabilities 225.69
Total Equity 148.03
Share Outstanding 12216600
Price to Book Ratio 5.31
Return on Assets (%) 6.60
Return on Capital (%) 8.65
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.08
Total Assets 192.18
Total Liabilities 192.18
Total Equity 134.35
Share Outstanding 12216600
Price to Book Ratio 4.86
Return on Assets (%) 6.49
Return on Capital (%) 8.23
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2.23
Total Assets 176.45
Total Liabilities 176.45
Total Equity 122.47
Share Outstanding 12216600
Price to Book Ratio 1.80
Return on Assets (%) 6.94
Return on Capital (%) 9.26
Particulars MAR 2024 (Values in Cr)
Net Income 9.49
Cash from Operations -3.67
Cash from Investing -5.56
Cash from Financing 6.31
Net change in Cash -5.99
Free Cash Flow 2.60
Particulars MAR 2023 (Values in Cr)
Net Income 14.72
Cash from Operations -3.16
Cash from Investing -5.88
Cash from Financing 29.12
Net change in Cash 16.95
Free Cash Flow 3.43
Particulars MAR 2022 (Values in Cr)
Net Income 14.89
Cash from Operations 7.30
Cash from Investing -8.47
Cash from Financing 4.29
Net change in Cash -0.06
Free Cash Flow 15.91
Particulars MAR 2021 (Values in Cr)
Net Income 12.12
Cash from Operations 17.23
Cash from Investing -17.81
Cash from Financing 5.83
Net change in Cash 0.79
Free Cash Flow 35.19
Particulars MAR 2020 (Values in Cr)
Net Income 13.29
Cash from Operations 17.15
Cash from Investing -37.29
Cash from Financing 19.06
Net change in Cash -5.42
Free Cash Flow 54.76
Particulars MAR 2024 (Values in Cr)
Net Income 13.29
Cash from Operations 2.81
Cash from Investing -8.71
Cash from Financing 3.13
Net change in Cash -5.82
Free Cash Flow 8.56
Particulars MAR 2023 (Values in Cr)
Net Income 15.00
Cash from Operations -6.62
Cash from Investing -7.54
Cash from Financing 27.66
Net change in Cash 16.62
Free Cash Flow -0.37
Particulars MAR 2022 (Values in Cr)
Net Income 14.90
Cash from Operations 8.01
Cash from Investing -8.47
Cash from Financing 4.39
Net change in Cash 0.73
Free Cash Flow 16.61
Particulars MAR 2021 (Values in Cr)
Net Income 12.48
Cash from Operations 17.43
Cash from Investing -17.81
Cash from Financing 5.68
Net change in Cash 0.85
Free Cash Flow 35.40
Particulars MAR 2020 (Values in Cr)
Net Income 12.25
Cash from Operations 16.06
Cash from Investing -39.35
Cash from Financing 21.35
Net change in Cash -6.28
Free Cash Flow 53.67
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 36.86 3.50 491.45 37.54 / 77.70
BLISS GVS PHARMA LTD 175.85 22.01 1.83 1852.87 92.25 / 179.65
CIPLA LTD 1447.35 25.32 4.12 116889.80 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 403.70 140.17 4.09 1188.13 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 64.13 55.77 10.90 491.45 37.54 / 77.70
AMRUTAJAN HEALTH LTD 749.90 45.61 7.28 2168.01 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6603.60 128.25 24.30 16509.00 4050.15 / 8139.85
BLISS GVS PHARMA LTD 175.85 22.93 1.80 1852.87 92.25 / 179.65

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 580.20
  • 26 Days 524.00
  • 10 Days 553.60
  • 50 Days 525.40
  • 12 Days 545.40
  • 100 Days 491.50
  • 20 Days 521.90
  • 200 Days 519.10
573.67
PIVOT
First Resistance 587.33
Second Resistance 603.12
Third Resistance 616.78
First Support 557.88
Second Support 544.22
Third Support 528.43
RSI 61.13
MACD 21.34
Commodity Channel Index (CCI) 77.40
ADX 36.46
Williams % R -32.59

Over 1 Month

down

25.21

Over 3 Months

down

20.59

Over 6 Months

down

18.99

Over 1 Year

down

-2.85

Over 3 Years

down

-11.05

Over 5 Years

down

0.00

MEDICAMEN BIOTECH LIMITED Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

MEDICAMEN BIOTECH LIMITED Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
55.77
Promoter Holdings
42.99
FII
0.06
DII
1.17
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Shivalik Rasayan Limited Shareholding of Promoter and Promoter Group 5466095.0 42.99
Pharmadanica A/s Public Shareholding 1340000.0 10.54
Sanjay Bansal Public Shareholding 202813.0 1.6
Ginnerup Capital Aps Public Shareholding 156600.0 1.23
Rajesh Madan Public Shareholding 154000.0 1.21
Ashish Chugh Public Shareholding 135171.0 1.06
Growel Remedies Limited Shareholding of Promoter and Promoter Group 0.0 0.0

MEDICAMEN BIOTECH LIMITED

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-09-20 1.0 Final 2023-09-21 Equity shares 2022-09-19 1.0 Final 2022-09-21 Equity shares 2021-09-16 1.0 Final 2021-09-19 Equity shares 2020-09-17 0.5 Final 2020-09-19 Equity shares 2019-09-17 1.0 Final 2019-09-18 Equity shares 2017-08-08 1.0 Interim 2017-08-09 Equity shares 2010-09-21 0.75 Final 2010-09-23 Equity shares
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Learn More About Stocks

About MEDICAMEN BIOTECH LIMITED

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by MEDICAMEN BIOTECH LIMITED

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Share Price of Medicamen Biotech Ltd?

Answer Field

The share price of Medicamen Biotech Ltd for NSE is ₹ 564.15 and for BSE is ₹ 563.1.

What is the Market Cap of Medicamen Biotech Ltd?

Answer Field

The market cap of Medicamen Biotech Ltd for NSE is ₹ 7,17.29 Cr. and for BSE is ₹ 7,15.95 Cr. as of now.

What is the 52 Week High and Low of Medicamen Biotech Ltd?

Answer Field

The 52 Week High and Low of Medicamen Biotech Ltd for NSE is ₹ 630.00 and ₹ 355.45 and for BSE is ₹ 630.00 and ₹ 356.75.

How to Buy Medicamen Biotech Ltd share?

Answer Field

You can trade in Medicamen Biotech Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Medicamen Biotech Ltd?

Answer Field

The 1 year returns on the stock has been -2.85%.

What is the Current Share Price of Medicamen Biotech Ltd?

Answer Field

Medicamen Biotech Ltd share price is for NSE ₹ 564.15 & for BSE ₹ 563.1 as on Dec 13 2024 03:29 PM.

What is the Market Cap of Medicamen Biotech Ltd Share?

Answer Field

The market cap of Medicamen Biotech Ltd for NSE ₹ 7,17.29 & for BSE ₹ 7,15.95 as on Dec 13 2024 03:29 PM.

What is the P/E Ratio of Medicamen Biotech Ltd Share?

Answer Field

As on Dec 13 2024 03:29 PM the price-to-earnings (PE) ratio for Medicamen Biotech Ltd share is 69.08.

What is the PB ratio of Medicamen Biotech Ltd Share?

Answer Field

As on Dec 13 2024 03:29 PM, the price-to-book (PB) ratio for Medicamen Biotech Ltd share is 173.40.

How to Buy Medicamen Biotech Ltd Share?

Answer Field

You can trade in Medicamen Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Medicamen Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Medicamen Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Medicamen Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader